One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
cbdMD logo
cbdMD YCBD
$ 0.38 -2.14%
report update icon

Quarterly report 2026-Q3
added 08-13-2026

cbdMD Balance Sheet 2025-2011 | YCBD

Brief balance sheet overview of cbdMD

The balance sheet is assessed across five available annual reports spanning 2021 to 2025.

Assets finished at $10.4 million versus $124.9 million initially, losing -91.7%. The balance sheet contracted.

Asset and liability trends were close, at -91.7% and -85.3%. Expansion did not materially reshape funding sources.

Equity accounts for 69.3% of assets. Against the initial 67.6%, the capital position looks resilient.

The cash share moved from 21.1% to 21.7%. A higher figure generally provides more room in an adverse scenario.

Retained earnings are negative at -$179.4 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.

Overall picture

cbdMD has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.

Annual Balance Sheet cbdMD

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - -521 K -5.42 M -25.2 M -13.1 M -4.69 M -4.28 M 75.8 K 763 K -215 K - - - -

Long Term Debt

- - 9 125 K 109 K 602 K - - 360 K - - - - - -

Long Term Debt Current

778 K 98.7 K 1.28 M 1.18 M 1.15 M 1.16 M - - - - - - - - -

Total Non Current Liabilities

- - 2.49 M 4.08 M 14.8 M 24 M 53.2 M 28.5 K 397 K 12 K 4 K - - - -

Total Current Liabilities

3.19 M 8.62 M 4.67 M 5.29 M 6.92 M 7.69 M 3.71 M 970 K 1.52 M - - - - - -

Total Liabilities

3.19 M 8.62 M 7.16 M 9.37 M 21.7 M 31.7 M 56.9 M 998 K 1.92 M 1.92 M 545 K - - - -

Deferred Revenue

506 K 503 K 185 K - - - 7.34 K 161 K 41.4 K - - - - - -

Retained Earnings

-179 M -182 M -174 M -147 M -73.3 M -47.4 M -59.6 M -6.67 M -6.26 M -4.49 M -1.13 M - - - -

Total Assets

10.4 M 10.6 M 16.2 M 40.8 M 125 M 111 M 94.5 M 15 M 7.07 M 1.62 M 1.82 M - - - -

Cash and Cash Equivalents

2.26 M 2.45 M 1.8 M 6.72 M 26.4 M 14.8 M 4.69 M 4.28 M 284 K 34.3 K - - - - -

Book Value

7.23 M 1.96 M 9.03 M 31.4 M 103 M 79.2 M 37.6 M 14 M 5.15 M -293 K 1.28 M - - - -

Total Shareholders Equity

7.23 M 1.96 M 9.03 M 26.6 M 84.4 M 85.7 M 55.5 M 12.6 M 4.21 M -293 K - - - - -

All numbers in USD currency

Quarterly Balance Sheet cbdMD

2026-Q3 2026-Q2 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 201 K 400 K 592 K - 1.58 M 1.82 M - 2.4 M 819 - - 125 K 128 K 77.7 K 93.5 K 109 K 124 K 109 K 5.69 M 264 K 6.01 M 6.01 M 6.91 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 201 K 400 K 592 K - 2.96 M 4.53 M 2.09 M 2.49 M 2.85 M 3.22 M 3.58 M 4.08 M 4.81 M 7.18 M 8.17 M 14.8 M 19.5 M 14.8 M 31.6 M 24 M 24 M 24 M 40.8 M 53.2 M 53.2 M 53.2 M 76.5 M 28.5 K 28.5 K 76.5 M 375 K 397 K 397 K 397 K - 12 K - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

3.19 M 2.97 M 2.77 M 3.19 M 3.78 M 10.3 M 9.76 M 8.62 M 10.8 M 11.5 M 8.06 M 7.16 M 7.24 M 7.9 M 9.14 M 9.37 M 10.5 M 13 M 14.9 M 21.7 M 26.2 M 21.7 M 38.4 M 31.7 M 31.7 M 31.7 M 46.3 M 56.9 M 56.9 M 56.9 M 78.3 M 998 K 998 K 78.3 M 1.14 M 1.92 M 1.92 M 1.92 M - 1.92 M - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

506 K 454 K 489 K 506 K 509 K 557 K 527 K 503 K 550 K 468 K - 188 K - - - - - - - - 755 - 22.4 K - - 45.1 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-179 M -181 M -180 M -179 M -179 M -185 M -183 M -182 M -181 M -180 M -176 M -174 M -157 M -155 M -152 M -147 M -132 M -99.2 M -93.5 M -73.3 M -69 M -73.3 M -56.9 M -47.4 M -47.4 M -47.4 M -46.8 M -59.6 M -59.6 M -59.6 M -11.3 M -6.67 M -6.67 M -7.25 M -7.39 M -6.26 M -6.26 M -6.26 M - -4.49 M - - - - - - - - - - - - - - - - - - - - - -

Total Assets

10.4 M 12.3 M 11.8 M 10.4 M 9.9 M 10.9 M 11.5 M 10.6 M 13.8 M 14.6 M 15.1 M 16.2 M 33 M 33.7 M 35.7 M 40.8 M 57.1 M 93 M 99.3 M 125 M 116 M 125 M 124 M 111 M 111 M 111 M 102 M 94.5 M 94.5 M 94.5 M 96.4 M 15 M 15 M 96.4 M 15.3 M 7.07 M 7.07 M 15.3 M 2.69 M 1.62 M - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

2.26 M 2.64 M 3.39 M 2.26 M 1.06 M 1.77 M 1.97 M 2.45 M 2.4 M 2.11 M 1.5 M 1.8 M 2.85 M 1.72 M 3.35 M 6.72 M 9.55 M 13.3 M 19.7 M 26.4 M 19 M 26.4 M 28.8 M 14.8 M 14.8 M 28.8 M 3.66 M 4.69 M 4.69 M 3.66 M 8.03 M 4.28 M 4.28 M 8.03 M 8.82 M 284 K 284 K 8.82 M 1.12 M 34.3 K - - - 546 K - - - - - - - - - - - - - - - - - -

Book Value

7.23 M 9.28 M 9.01 M 7.23 M 6.11 M 666 K 1.78 M 1.96 M 3.03 M 3.09 M 7.04 M 9.03 M 25.7 M 25.8 M 26.6 M 31.4 M 46.6 M 80 M 84.4 M 103 M 89.3 M 103 M 85.7 M 79.2 M 79.2 M 79.2 M 55.5 M 37.6 M 37.6 M 37.6 M 18.1 M 14 M 14 M 18.1 M 14.2 M 5.15 M 5.15 M 13.4 M 2.69 M -293 K - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

1.96 M 9.28 M 9.01 M 7.23 M 6.11 M 666 K 1.78 M 1.96 M 3.03 M 3.09 M 7.04 M 9.03 M 25.7 M 25.8 M 26.6 M 31.4 M 46.6 M 80 M 84.4 M 103 M 89.3 M 85.9 M 85.7 M 85.7 M 85.7 M 85.7 M 55.5 M 55.5 M 55.5 M 55.5 M 18.1 M 14 M 12.6 M 16.8 M 13.4 M 4.21 M 4.21 M 4.21 M - 363 K - - - 1.28 M - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of cbdMD, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Drug manufacturers

Issuer Price % 24h Market Cap Country
Perrigo Company plc Perrigo Company plc
PRGO
$ 15.91 -1.64 % $ 2.2 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 8.17 2.64 % $ 121 M usaUSA
Evolus Evolus
EOLS
$ 7.4 0.41 % $ 477 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 3.96 -0.25 % $ 217 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.2 -1.43 % $ 332 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.33 -0.14 % $ 1.62 B usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.08 -2.07 % $ 255 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 6.41 0.16 % $ 561 M usaUSA
Tilray Tilray
TLRY
$ 2.92 -3.63 % $ 327 M canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.9 1.06 % $ 22 M usaUSA
Veru Veru
VERU
$ 2.3 -3.36 % $ 33.7 M usaUSA
Viatris Viatris
VTRS
$ 18.45 -1.07 % $ 21.2 B usaUSA
Harrow Health Harrow Health
HROW
$ 28.24 0.61 % $ 1.04 B usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.67 -6.67 % $ 200 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.99 -2.81 % $ 125 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.79 -0.39 % $ 189 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.28 0.39 % $ 330 M canadaCanada
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.14 -0.87 % $ 1.92 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.94 0.38 % $ 89.6 M canadaCanada
Bausch Health Companies Bausch Health Companies
BHC
$ 6.45 0.55 % $ 2.39 B canadaCanada
Cronos Group Cronos Group
CRON
$ 3.39 3.35 % $ 1.3 B canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.7 -3.78 % $ 3 M chinaChina
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 3.21 -4.46 % $ 127 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA